César Germán Prucca

Prof. Dr. César Germán Prucca

DQBRC-FCQ-UNC, CIQUIBIC-CONICET. Centro de Investigaciones en Quimica Biológica de Córdoba., Córdoba, Argentina
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2008 in Nature
Verified
Journal Article
Closed access
PDF file
César Germán PruccaCésar Germán Prucca
César Germán Prucca
ISIleana Slavin
Ileana Slavin
RQRodrigo Quiroga
Rodrigo Quiroga
EEEliana V. Elías
Eliana V. Elías
FRFernando D. Rivero
Fernando D. Rivero
HLHugo D. Luján
Hugo D. Luján

21 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMarianela C. Serradell
Marianela C. Serradell
LRLucía L. Rupil
Lucía L. Rupil
RMRomán A. Martino
Román A. Martino
César Germán PruccaCésar Germán Prucca
César Germán Prucca
PCPedro G. Carranza
Pedro G. Carranza
HLHugo D. Luján
Hugo D. Luján
Intestinal and free-living protozoa, such as Giardia lamblia, express a dense coat of variant-specific surface proteins (VSPs) on trophozoites that protects the parasite inside the host’s intestine. Here we show that VSPs not only are resistant to proteolytic digestion and extreme pH and temperatures but also stimulate host innate immune responses in a TLR-4 dependent manner. We show that these properties can be exploited to both protect and adjuvant vaccine antigens for oral administration. Chimeric Virus-like Particles (VLPs) decorated with VSPs and expressing model surface antigens, such as influenza virus hemagglutinin (HA) and neuraminidase (NA), are protected from degradation and activate antigen presenting cells in vitro. Orally administered VSP-pseudotyped VLPs, but not plain VLPs, generate robust immune responses that protect mice from influenza infection and HA-expressing tumors. This versatile vaccine platform has the attributes to meet the ultimate challenge of generating safe, stable and efficient oral vaccines.

1 December 2009 in Cellular Microbiology
Verified
Journal Article
Closed access
PDF file
César Germán PruccaCésar Germán Prucca
César Germán Prucca
HLHugo D. Lujan
Hugo D. Lujan
Giardia lamblia undergoes antigenic variation, both in vitro and within the intestines of infected individuals. Variant-specific surface proteins (VSPs) cover the entire surface of the trophozoites and are the main antigens recognized by the host. Only 1 of about 200 VSP genes encoded by the Giardia genome is expressed on the surface of individual Giardia cells at any time; however, VSP antigen switching occurs spontaneously. In the recent year, significant advances in the knowledge of the antigen switching process have been achieved, which strongly suggests that antigenic variation in Giardia is regulated at the post-transcriptional level by a mechanism similar to RNA interference (RNAi). Several enzymes of the RNAi pathway are directly involved in VSP mRNA silencing and/or translational repression. Although several questions remain regarding how individual VSP antigens are selected for expression on the parasite surface, it is clear that an epigenetic mechanism is involved. In this review, we summarize the characteristics of this fascinating mechanism, analyse conflicting information regarding the structure of VSPs as it relates to the host's immune response, and highlight the major issues that need to be resolved to fully understand antigenic variation in this important pathogen.

25 April 2010 in Nature Medicine
Verified
Journal Article
Closed access
FRFernando D Rivero
Fernando D Rivero
ASAlicia Saura
Alicia Saura
César Germán PruccaCésar Germán Prucca
César Germán Prucca
PCPedro G Carranza
Pedro G Carranza
ATAlessandro Torri
Alessandro Torri
HLHugo D Lujan
Hugo D Lujan

1 January 2006 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
MAM. Gabriela Alvarez
M. Gabriela Alvarez
César Germán PruccaCésar Germán Prucca
César Germán Prucca
MMM. Elisa Milanesio
M. Elisa Milanesio
EDEdgardo Durantini
Edgardo Durantini
VRViviana Rivarola
Viviana Rivarola

13 October 2011 in Annual Review of Microbiology
Verified
Journal Article
Closed access
César Germán PruccaCésar Germán Prucca
César Germán Prucca
FRFernando D. Rivero
Fernando D. Rivero
HLHugo D. Luján
Hugo D. Luján
Antigenic variation, a clonal phenotypic variation developed by microorganisms, involves the permanent switching of homologous, antigenically different cell surface molecules. In pathogenic microorganisms, antigenic variation is often described as a mechanism to evade the host immune system and therefore is responsible for the generation of chronic and/or recurrent infections. However, antigenic variation has also been involved in expanding host diversity and differential courses of the diseases. The intestinal protozoan parasite Giardia lamblia undergoes antigenic variation through the continuous exchange of approximately 200 variant-specific surface proteins. Here we review the principal issues regarding the significance of antigenic variation during Giardia infections, the particular features of the variant-specific surface proteins, and the current knowledge on the mechanisms that regulate this process, as well as the relevance of disrupting antigenic variation as a novel approach to design effective antiparasitic vaccines.